Alterity Therapeutics Ltd Adr (ATHE)

Apr 10, 2025

Alterity shares new phase 2 data on MSA treatment - Investing.com

Apr 10, 2025

Apr 07, 2025

Alterity Therapeutics announces regulatory notice - Investing.com

Apr 07, 2025

Apr 07, 2025

Alterity Therapeutics completes placement - Investing.com

Apr 07, 2025

Apr 07, 2025

Alterity Therapeutics announces regulatory notice By Investing.com - Investing.com UK

Apr 07, 2025

Apr 07, 2025

Alterity Therapeutics completes placement By Investing.com - Investing.com UK

Apr 07, 2025

Mar 27, 2025

ATHEAlterity Therapeutics Ltd Latest Stock News & Market Updates - Stock Titan

Mar 27, 2025

Mar 27, 2025

Alterity Concludes Open-Label Trial Patient Visits - Investing.com

Mar 27, 2025

Feb 18, 2025

Alterity Therapeutics announces compliance notice - Investing.com

Feb 18, 2025

Feb 18, 2025

Alterity Therapeutics Issues Over 1 Billion New Shares - TipRanks

Feb 18, 2025

Feb 13, 2025

Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsight - GlobeNewswire Inc.

Feb 13, 2025

Feb 10, 2025

Alterity Therapeutics raises A$40M in placement - TipRanks

Feb 10, 2025

Feb 10, 2025

Alterity secures funding to advance MSA drug development - Investing.com India

Feb 10, 2025

Feb 06, 2025

JPMorgan Ceases Substantial Holding in Alterity Therapeutics - TipRanks

Feb 06, 2025

Feb 06, 2025

Alterity Therapeutics announces trading halt - Investing.com

Feb 06, 2025

Feb 05, 2025

Alterity Therapeutics Initiates Trading Halt for Capital Raising Announcement - TipRanks

Feb 05, 2025

Feb 05, 2025

JPMorgan Becomes Substantial Holder in Alterity Therapeutics - TipRanks

Feb 05, 2025

Feb 05, 2025

Alterity Therapeutics reports compliance with Takeovers Panel By Investing.com - Investing.com South Africa

Feb 05, 2025

Feb 05, 2025

Alterity Therapeutics reports compliance with Takeovers Panel - Investing.com

Feb 05, 2025

Feb 04, 2025

Alterity Therapeutics Discloses Equity Derivative Positions of Point72 - TipRanks

Feb 04, 2025

Feb 04, 2025

Alterity Therapeutics announces securities notice - Investing.com

Feb 04, 2025

Feb 03, 2025

Alterity Therapeutics Completes Significant Share Issuance - TipRanks

Feb 03, 2025

Feb 03, 2025

Alterity Therapeutics Quotes Over 164 Million Securities on ASX - TipRanks

Feb 03, 2025

Feb 03, 2025

Alterity Therapeutics announces ATH434 Phase 2 trial results - MSN

Feb 03, 2025

Feb 02, 2025

Alterity Therapeutics Announces Major Securities Placement - TipRanks

Feb 02, 2025

Feb 02, 2025

Alterity Therapeutics Secures Funding to Advance Neurodegenerative Drug Development - TipRanks

Feb 02, 2025

Jan 29, 2025

Alterity Therapeutics Reports Promising Phase 2 Results for MSA Drug ATH434 - TipRanks

Jan 29, 2025

Jan 27, 2025

Alterity Therapeutics Initiates Trading Halt Pending Phase II Trial Results - TipRanks

Jan 27, 2025

Jan 25, 2025

Predictive Oncology Inc (NASDAQ: POAI) Stock Is A Good Option To Consider - Stocks Register

Jan 25, 2025

Jan 24, 2025

Alterity Therapeutics reports quarterly activities - Investing.com

Jan 24, 2025

Jan 24, 2025

Alterity Therapeutics reports quarterly activities By Investing.com - Investing.com UK

Jan 24, 2025

Jan 23, 2025

Alterity Therapeutics Advances ATH434 Clinical Trials with Promising Data - TipRanks

Jan 23, 2025

Jan 22, 2025

Alterity Therapeutics Expands ASX Quoted Securities - TipRanks

Jan 22, 2025

Jan 21, 2025

Alterity Therapeutics Reports Key Advances and Anticipates Milestones in 2025 - TipRanks

Jan 21, 2025

Jan 16, 2025

Alterity Therapeutics Highlights Key Milestones in Neurodegenerative Disease Pipeline - TipRanks

Jan 16, 2025

Jan 07, 2025

Opthea reports positive Phase 1b DME trial results - Investing.com

Jan 07, 2025

Dec 31, 2024

ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead

Dec 31, 2024

Dec 04, 2024

ASX November Health Winners: Paradigm, Imricor lead sector as momentum returns - Stockhead

Dec 04, 2024

Nov 23, 2024

Alterity Therapeutics reports annual general meeting results By Investing.com - Investing.com South Africa

Nov 23, 2024

Nov 22, 2024

Alterity Therapeutics reports annual general meeting results - Investing.com India

Nov 22, 2024

Nov 19, 2024

Alterity Therapeutics announces change in company secretary - Investing.com

Nov 19, 2024

Nov 19, 2024

Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary - Yahoo Finance

Nov 19, 2024

Nov 15, 2024

Opthea adds Kathy Connell to Board of Directors - Investing.com

Nov 15, 2024

Oct 15, 2024

Alterity Therapeutics to join Maxim Healthcare Summit - Investing.com

Oct 15, 2024

Oct 04, 2024

Alterity Therapeutics announces change in share registry By Investing.com - Investing.com UK

Oct 04, 2024

Feb 15, 2024

Check Up: Aussie biotech Avarax on the verge of peanut allergy cure; and recent ASX health winners - Stockhead

Feb 15, 2024

Aug 17, 2023

Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money ... - Stockhead

Aug 17, 2023

Jan 06, 2023

Alterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation) - PR Newswire

Jan 06, 2023